The Patent Finder
US

Piperidinone Carboxamide Azaindane CGRP Receptor Antagonists

US 9,499,545 In force
OverviewFamilyAssignmentsSources & methods

Also listed on Merck Sharp & Dohme LLC, which filed it. The recorded assignments below show how it moved.

Term ends Nov 10, 2031 · Medium confidence

Held by Merck Sharp & Dohme LLC
Filed Sep 12, 2014 · Granted Nov 22, 2016
Base term, 20 years from filing
Today
20 years from filing
2011 2031
Clock starts
Nov 10, 2011
Term ends
Nov 10, 2031
Granted
Nov 22, 2016
base term fee events Updated Nov 1, 2026 · includes USPTO assignment & status data published Nov 1, 2026 and grant & fee data published Oct 27, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 8,481,556, US 8,754,096, US 8,912,210, US 9,499,541, to Nov 10, 2031. The term already ends on or before that date, so the cap shortened nothing.
2 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
10
Applications in this family
Applications sharing this one's continuity chain.

This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 2 of 3 maintenance fees are paid so far. Confidence: Medium. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
StepInputDate after this stepConfidence
Base term, 20 years from filingClock starts Nov 10, 2011Nov 10, 2031High confidence
Continuity chainEvery parent in the chain resolvedno changeHigh confidence
Patent term adjustmentNone on fileno changeHigh confidence
Terminal disclaimer capDisclaimer resolved from the filed document (refs US 8,481,556, US 8,754,096, US 8,912,210, US 9,499,541)resolves to Nov 10, 2031, no earlier than this term, so no changeMedium confidence
Patent term extensionNone on fileno changeHigh confidence
Fee events2 of 3 maintenance fees paidIn forceHigh confidence
Computed term endThe steps above, in orderNov 10, 2031Medium confidence

This family

Application 61/413,077Provisional application
no patent term
no patent term
Application 61/425,034Provisional application
no patent term
no patent term
US 8,912,210In force
Dec 2033
Dec 2033
US 8,754,096In force
Jun 2036
Jun 2036
US 8,481,556In force
Nov 2031
Nov 2031
US 9,499,545this patent
Nov 2031
Nov 2031
US 9,833,448In force
Nov 2031
Nov 2031
US 10,272,077In force
Nov 2031
Nov 2031
8 of 10 applications in this family shown, earliest filings first.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
RecordedAssignorAssigneeConveyance
Aug 17, 2015
Reel 36341, frame 397
Bell, Ian M.; Fraley, Mark E.; Gallicchio, Steven N.; Ginnetti, Anthony; Mitchell, Helen J.; Paone, Daniel V.; Staas, Donnette D.; Wang, Cheng; Zartman, C. BlairMerck Sharp & Dohme Corp.Assignment of Assignor's Interest
Aug 8, 2022
Reel 61102, frame 145
Merck Sharp & Dohme Corp.Merck Sharp & Dohme LLCMerger

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

Maintenance fee events come from USPTO's own fee records. USPTO does not publish a per-patent fee page, so there is nothing to link to.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.

What's changing

Terminal disclaimer

A terminal disclaimer resolved from the filed document, referencing US 8,481,556, US 8,754,096, US 8,912,210, US 9,499,541, ends no earlier than this term, so it caps nothing.

Citations

18
later US patents cite this one
That is top 25% of utility patents granted in 2016 in our data, the only group it is compared against. How we rank
Every date shows its work: base rule, PTA, PTE, disclaimer caps, fee overlay, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 1, 2026 · includes USPTO assignment & status data published Nov 1, 2026 and grant & fee data published Oct 27, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited